Boehringer Ingelheim Pharmaceuticals | Jobs at Boehringer Ingelheim Pharmaceuticals
In view of increasing demand for innovative inhalation system, the research-driven pharma company - Boehringer Ingelheim Corporation is investing approximately Euro 85 million ($110 Million) in its Dortmund facility to double the Respimat soft inhalers production to 44 million annually by 2015. Will add 100 to Headacount, According to Sources.
A successful treatment of respiratory diseases depends on how much of the active substance enters into the patient's lung. Boehringer Ingelheim's Respimat soft inhaler and its long-lasting aerosol cloud effectively transport the active substance into the patient's lung.
In view of increasing demand for innovative inhalation system, the research-driven pharma company - Boehringer Ingelheim Corporation is investing approximately Euro 85 million ($110 Million) in its Dortmund facility to double the Respimat soft inhalers production to 44 million annually by 2015. Will add 100 to Headacount, According to Sources.
A successful treatment of respiratory diseases depends on how much of the active substance enters into the patient's lung. Boehringer Ingelheim's Respimat soft inhaler and its long-lasting aerosol cloud effectively transport the active substance into the patient's lung.
